Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

Jin KangHua-Jun ChenXu-Chao ZhangJian SuQing ZhouHai-Yan TuZhen WangBin-Chao WangWen-Zhao ZhongXue-Ning YangZhi-Hong ChenYan DingXue WuMei WangJian-Gang FuZhenfan YangXian ZhangYang W ShaoYi-Long WuJin-Ji Yang

Published in: Thoracic cancer (2018)

Heterogeneous resistant mechanisms have been identified and correlate to diverse responses to crizotinib. Comprehensive and dynamic mutation profiling is required to better predict clinical outcomes.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
single cell